Biocon, a global biopharmaceutical company, has appointed Peter Bains as Group CEO with immediate effect after receiving approval from the Board. He will be reporting directly to the group chairperson Kiran Mazumdar Shaw.
Peter, who was serving the company’s board in the capacity of an independent director, has stepped down to assume his new role.
Announcing leadership rejigs at the pharmaceuticals, the group chairperson Kiran stated, “Biocon is entering a dynamic phase of growth for its 3 core businesses, Biocon Biologics, Biocon Generics and Syngene, and for the Group as a whole. I am delighted to welcome Peter back to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Ltd., Shreehas Tambe, CEO & MD Biocon Biologics Ltd. and Jonathan Hunt, CEO & MD Syngene International Ltd. will continue to have independent charge of their businesses and will work with Peter to strengthen synergistic strategic leadership at a Group level to maximise the combined value of all 3 businesses.”
Extending her wishes to the new group CEO, she added, “Peter has a unique fit and profile for the role, with extensive global leadership experience and success in the biopharmaceutical field, as well as a comprehensive understanding of the Biocon Group. He led Syngene for five years, taking it through its highly successful IPO in 2015. I am confident that this appointment will serve the integrated business objectives of the Biocon Group of companies and deliver added value to all stakeholders.”
Peter brings over 30 years of industry experience, with a proven track record in strategic and operational leadership roles. Throughout his career, he has excelled in building brands, businesses, teams, and companies. His previous key leadership positions include serving as a non-executive director at Indivior Plc, CEO and board director at Heptares Therapeutics Ltd, non-executive director and Chief Business Officer at MiNA Therapeutics Ltd, CEO and Board Director at Syngene International Ltd, and Senior VP of Commercial Development (International) at GSK.